Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib

BACKGROUND: Anlotinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis which has shown activity in several malignancies and approved for the treatment of small cell lung cancer (SCLC) in China. However, there are no markers can predict the clinical outcomes of anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingjing, Li, Shuang, Zhang, Shuang, Yang, Changliang, Zhang, Liang, Zhang, Bin, Cheng, Ying, Wang, Changli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656377/
https://www.ncbi.nlm.nih.gov/pubmed/33209408
http://dx.doi.org/10.21037/jtd-20-755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656377/
https://www.ncbi.nlm.nih.gov/pubmed/33209408
http://dx.doi.org/10.21037/jtd-20-755

Ejemplares similares